Cargando…

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

The administration of azacitidine (AZA) was found to be more effective than conventional care regimen (CCR) in patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) with lower blast count. We designed a study to determine e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helbig, Grzegorz, Chromik, Karolina, Woźniczka, Krzysztof, Kopińska, Anna J., Boral, Kinga, Dworaczek, Martyna, Koclęga, Anna, Armatys, Anna, Panz-Klapuch, Marta, Markiewicz, Mirosław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614132/ https://www.ncbi.nlm.nih.gov/pubmed/30613922 http://dx.doi.org/10.1007/s12253-018-00574-0

Ejemplares similares

Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation
por: Helbig, Grzegorz, et al.
Publicado: (2020)

Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience
por: Duda, Katarzyna, et al.
Publicado: (2023)

Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
por: Duda, Katarzyna, et al.
Publicado: (2021)

Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
por: Zielinska, Patrycja, et al.
Publicado: (2014)

Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
por: Tendas, Andrea, et al.
Publicado: (2014)

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia
por: Čemažar, Luka, et al.
Publicado: (2020)

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
por: Islam, Anwarul
Publicado: (2023)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Chesnais, Virginie, et al.
Publicado: (2012)

Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
por: Spałek, Adrianna, et al.
Publicado: (2022)

P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
por: Koenig, Kristin, et al.
Publicado: (2023)

Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenström’s Macroglobulinemia
por: Kopińska, Anna J., et al.
Publicado: (2017)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia
por: Weeks, Lachelle D., et al.
Publicado: (2022)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center
por: Kopińska, A., et al.
Publicado: (2021)

Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia
por: Niscola, Pasquale, et al.
Publicado: (2015)

P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL
por: Ross, David, et al.
Publicado: (2023)

Vasculitis in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: A Report of Two Cases
por: Jacobse, Justin, et al.
Publicado: (2018)

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine
por: Kumode, Takahiro, et al.
Publicado: (2014)

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature
por: Elli, Elena, et al.
Publicado: (2012)

Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
por: Nakako, Soichiro, et al.
Publicado: (2021)

PB2033: ADVANCED CHRONIC MYELOMONOCYTIC LEUKEMIA IN ELDERLY AND FRAIL PATIENTS MANAGED BY AZACITIDINE IN THE FIELD OF CLINICAL PRACTICE.
por: Niscola, Pasquale, et al.
Publicado: (2023)

TET2 mutational status affects myelodysplastic syndrome evolution to chronic myelomonocytic leukemia
por: Quang, Violaine Tran, et al.
Publicado: (2023)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Pericole, Fernando Vieira, et al.
Publicado: (2019)

Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Jachiet, Vincent, et al.
Publicado: (2021)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Tan, P, et al.
Publicado: (2014)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8nq7dj91p4o8d32hovvbhi18ea